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Inconsistent expression and regulation of drug-metabolizing enzymes (DMEs) are common causes of adverse drug eﬀects in some
drugswithanarrowtherapeuticindex(TI).Animportantcytochrome,cytochromeP4503A4(CYP3A4),ispredominantlyregula-
tedbyanuclearreceptor,pregnaneXreceptor(PXR).Sesamin,amajorlignanconstituentinsesameseedsandoil,exhibitsavariety
ofbiologicalfunctions;however,theeﬀectofsesaminonthemodulationofCYP3A4isnotwellunderstood.Inthisstudy,theeﬀects
of sesamin on the PXR-CYP3A4 pathway were characterized, as well as the underlying mechanisms of those eﬀects. Sesamin pot-
ently attenuated CYP3A4 induction in a dose-dependent manner by blocking the activation of PXR. The PXR inducer-mediated
inhibition of CYP3A4 was further evidenced by the ability of sesamin to attenuate the eﬀects of several PXR ligands in the CYP3A4
reporter assay. Further mechanistic studies showed that sesamin inhibited PXR by interrupting the interacting with coregulators.
These results may lead to the development of new therapeutic and dietary approaches to reduce the frequency of inducer-drug
interaction. Sesamin was established as a novel inhibitor of PXRand may be useful for modulating DMEs expression and drugeﬃ-
cacies. Modiﬁcation of CYP3A4 expression and activity by consumption of sesamin may have important implications for drug
safety.
1.Introduction
Sesame seeds (Sesamum indicum) and their oil have been
used in human diets for thousands of years and are believed
to provide health beneﬁts. A major constituent of sesame is
a lignan called sesamin. Sesamin has a variety of biological
functions including reduction of serum and hepatic choles-
terol levels [1–5]a sw e l la ss e r u mt r i g l y c e r i d e s[ 6] by in-
creasinghepaticfattyacidoxidation[1,2].Sesamin’sinvolve-
ment in the suppression of hypertension [7, 8]a n ds t r o k e
prevention has been extensively studied by many researchers
[9]. Moreover, sesamin has been shown to elevate the levels
of γ-tocopherol [10]; decrease production of endotoxin-
induced interleukin (IL)-1β, prostaglandin E2 (PGE2), and
thromboxane B2 [11]; elevate the production of IL-6 [12],
thus inhibiting endotoxin-mediated shock [11]. Some stud-
ies also suggest that sesamin has an inhibitory eﬀect on 7,12-
dimethylbenz[a]anthracene-induced mammary carcinogen-
esis [13] and inhibits the growth of a variety of neoplastic
cellsthroughdiﬀerentmechanisms[14–18].Thus,sesaminis
believed to protect against cancer and other chronic diseases.
Cytochrome P450- (CYP450-) dependent monooxyge-
nase occupies a pivotal role in the metabolism and detoxi-
ﬁcation process of endogenous and exogenous compounds
[19]. CYP3A4 is the most abundant CYP450 and has clinical
importance because it metabolizes numerous pharmaceuti-
cal agents [19]. It is highly expressed in the liver and intestine
and represents 40% of the total hepatic and 80% of the total2 Evidence-Based Complementary and Alternative Medicine
intestinal CYPs [20, 21]. CYP3A4 is also involved in the
metabolism of endogenous substrates (retinoic and bile
acids) and steroidal hormones (testosterone and estrogen)
[22]. In addition, dietary and environmental chemicals such
as aﬂatoxin B1 and some herbicides are also CYP3A4 sub-
strates [23, 24]. The expression and activity of CYP3A4
are greatly impacted by many drugs and dietary chemicals
suchasrifampin(anantibiotic),carbamazepine(ananticon-
vulsant), glucocorticoids, and hyperforin (a major compo-
nent of St. John’ wort) [25]. Individual variations in drug
metabolism may be due to the diﬀerential expression of the
CYP3A4enzyme,inducedbysomeofthesecompounds[20].
CYP3A4 protein expression in hepatocytes varies more than
50 folds among individuals, and the enzymatic activity varies
by at least 20 folds [26]. Changes caused by drug-metaboliz-
ing enzymes (DMEs) are common and undesirable, and
these enzymes inﬂuence the therapeutic eﬀects of drugs, par-
ticularly those having a narrow therapeutic index [27]. Since
CYP3A4activitymaybeaﬀectedbysomexenobiotics,itplays
a crucial role in drug-drug interactions. For example, coad-
ministration with rifampin, phenytoin, or carbamazepine
m a yr e d u c ep l a s m ac o n c e n t r a t i o n so fab r o a dr a n g eo f
CYP3A4 drug substrates to less than a half [28].
Compounds that modulate the upper control element of
CYP3A4, human pregnane X receptor (PXR), can also mod-
ulate CYP3A4 expression and drug metabolism activity [29–
31] .H u m a nP X Ri sam e m b e ro ft h en u c l e a rr e c e p t o r( N R )
superfamily, encoded by the NR1I2 gene [29–33]. PXR regu-
lates the expression of many enzymes involved in the meta-
bolism of xenobiotic and endobiotic compounds such as
CYP2B, CYP2C, CYP3A, glutathione S-transferases (GSTs),
sulfotransferases (SULTs), and uridine diphosphate (UDP)-
glucuronosyltransferases [34–37]. Beside phase I and phase
II drug metabolizing enzymes, PXR also regulates the exp-
ression of phase III enzymes, including the drug transporters
OATP2, MDR1, MRP2, and MRP3 [38, 39]. Being a ligand-
activatedtranscriptionfactor,PXRisactivatedbyavastarray
ofnaturalandsyntheticcompounds,includingtheantibiotic
rifampin [31], the antihypertension drug nifedipine, the
antimycotic drug clotrimazole [31, 32], the antiglucocorti-
coid RU-486 [32], and a variety of naturally occurring ste-
roids.
The PXR pathway is also activated by a large number of
prescription drugs designed to treat infection, cancer, con-
vulsions, and hypertension and is believed to play an impor-
tant role in drug metabolism and eﬄux as well as inducer-
drug interactions [40]. PXR increases the transcription of
CYP3A4 as well as other DMEs and transporters after expo-
sure to its agonists [41, 42]. Because many anticancer agents
have narrow therapeutic indices, modulation of the PXR-
CYP3A4 pathway may cause unpredictable eﬃcacy.
Because the PXR-CYP3A4 pathway is extremely impor-
tant in drug eﬃcacy, it is very important to ﬁnd an agent
that may reduce the eﬀect of inducer-drug interaction. PXR
antagonists may be useful for the study of the molecular
basis of receptor function. Although many PXR agonists
have been reported, comparatively few PXR compounds
antagonizing the PXR-CYP3A4 pathway have been identiﬁed
[43–47].
In this study, the eﬀects of sesamin on the PXR-CYP3A4
pathway and the underlying mechanisms were characterized.
Sesamin potently attenuated CYP3A4 induction in a dose-
dependent manner by blocking the activation of nuclear
receptors, especially PXR through CYP3A4 reporter assay.
The PXR inducer-mediated inhibition of CYP3A4 was fur-
ther evidenced by the ability of sesamin to attenuate the
eﬀects of rifampin, paclitaxel, and SR12813 in the CYP3A4
reporter assay. Further mechanistic studies showed that sesa-
min inhibited PXR by interrupting the binding of steroid
receptorcoactivator-1(SRC-1)andhepatocytenuclearfactor
4α(HNF4α).Ourresultsmayleadtothedevelopmentofim-
portant new therapeutic and dietary approaches to reduce
the frequency of undesirable drug interactions. Here, we
established sesamin as a novel and natural potent inhibitor
of PXR and proved that it can be a usefultool for modulating
DMEs expression. Modiﬁcation of CYP3A4 by consumption
ofsesamincouldhaveimportantimplicationsfordrugsafety.
2.MaterialsandMethods
2.1. Chemicals and Cell Cultures. Rifampin (RIF), sesamin
(SSM), 5-pregnen-3β-ol-20-one-16α-carbonitrile (PCN), 6-
(4-chlorophenyl)imidazo [2,1-b][1,3]thiazole-5-carbalde-
hyde O-(3,4-dichlorobenzyl)oxime (CITCO), SR12813, and
paclitaxel were purchased from Sigma-Aldrich (St. Louis,
MO, USA) and dissolved in DMSO at concentrations appro-
priateforthespeciﬁcstudiesinwhichtheywereused.HepG2
and LS174T cells were purchased from the Food Industry
Research and Development Institute (FIRDI, Taiwan, ROC)
and maintained in a minimum essential medium (MEM) α
mediumsupplementedwith10%fetalbovineserumwithout
antibiotics, in a 5% CO2 atmosphere at 37◦C.
2.2. Plasmids Construction. Plasmids pcDNA3-PXR and
pGL3B-CYP3A4 [(−444/+53)(−7836/ −7208)], containing
full-length human PXR and CYP3A4 promoter constructs,
respectively, have been described previously [48]. Full-length
SRC-1plasmidswerekindlyprovidedbyLih-YuhChenWing
(Department of Physiology, National Cheng Kung Univer-
sity, Tainan, Taiwan). A fragment encoding residues 595–
800 of the human SRC-1 (GenBank accession number
U90661) receptor interacting domain (RID) and the full-
length PXR were cloned into the pBIND-GAL4 and pACT-
VP16 vectors to prepare pBIND-SRC-1 and pACT-PXR, res-
pectively, as described previously [49]. The expression plas-
mids pcDNA3-HNF4α, pBIND-PXR, and pACT-HNF4α
were prepared as described previously [50]. A full-length
human constitutive androstane receptor (CAR) cDNA (Gen-
Bank accession number NM 001077480) was purchased
from Open Biosystems (Huntsville, AL, USA), and full-
length rat PXR (GenBank accession number NM 052980)
was cloned from rat liver cDNA. Both gene products were
ampliﬁed from cDNA (for human CAR: forward primer,
5 -AAG GAT CCA CGT CAT GGC CAG TAG-3 ;r e v e r s e
primer, 5 -CCA ATC TAG AGC ATT TTC CCA CTC-
3 ; for rat PXR: forward primer, 5 -GAT GGG ATC CTG
G A GA T GA G AC C TG A GG - 3  ; reverse primer, 5 -CTCEvidence-Based Complementary and Alternative Medicine 3
Table 1: Primer sequences used for real-time polymerase chain reaction.
Gene Primer sequence (5 –3 ) PCR condition
CYP3A4 (F) 5 -GGG AAG CAG AGA CAG GCA AG-3 
Denaturation (30s at 95◦C)
(R) 5 - G A GC G TT T CA T TC A CC A CC A - 3  
UGT1A1 (F) 5 -TTT TGT CTG GCT GTT CCC ACT-3 
Annealing (30s at 60◦C)
(R) 5 -GAA GGT CAT GT GAT CTG AAT GAG A-3 
NQO1 (F) 5 -CCA TTC TGA AAG GCT GGT TTG-3 
Extension (30s at 72◦C)
(R) 5 -CTA GCT TTG ATC TGG TTG TC-3 
β-actin (F) 5 -GTG GGG CGC CCC AGG CAC CA-3 
45 cycles
(R) 5 -CAC CCC GCG GGG TCC GTG GT-3 
(F): forward primer; (R): reverse primer.
ATC TAG AGC CAC TCA GCC GTC CGT G-3 ). The poly-
merase chain reaction (PCR) product was digested with
BamHIandXbaI,andrestrictionenzymecutsiteswereintro-
ducedintotheprimersbeforeperformingPCR.Thecutfrag-
ments were cloned into the pcDNA3 vectors with corre-
sponding restriction enzyme sites to generate pcDNA3-CAR
and pcDNA3-rPXR. The reporter construct pG5luc and an
internal control plasmid, pRC-CMV-β-galactosidase, were
purchased directly from Promega (Madison, WI, USA) and
Invitrogen (Groningen, Netherlands), respectively.
2.3. Assessment of Cell Cytotoxicity. To verify ≥80% cell via-
bility following xenobiotic exposure, cell viability was evalu-
ated using the modiﬁed acid-phosphatase (ACP) assay, with
p-nitrophenyl phosphate (PNPP) disodium salt as a subs-
trate. The cell culture media were aspirated, and the cells
were washed with phosphate-buﬀered saline (PBS). Follow-
ing the wash, 100μL of the ACP reagent [(0.1M sodium
acetate (pH 5.5), 0.1% Triton X-100, and 10mM PNPP)]
were added. After 1h of incubation at 37◦C, the enzyme
activity was stopped by adding 10μL of 1N NaOH, and the
extent of activity was determined photometrically at a wave-
length of 405nm [50].
2.4. Determination of CYP3A4 Enzymatic Activity. CYP3A4
enzyme activity was measured using the P450-Glo assay
(Promega). This assay measures CYP3A4 enzyme activity by
using luciferin-PFBE as a speciﬁc substrate for CYP3A4.
Brieﬂy, cells (1 × 105/well) were seeded into a 48-well plate
and treated with various concentrations of sesamin alone
or in combination with 20μM rifampin. After 48h of incu-
bation, the medium was discarded, and the cells were rinsed
twice with PBS. Fresh complete medium, containing 50μM
luciferin-PFBE, was added to the cells and incubated for 4h
at 37◦C. Subsequently, 50μL of the medium from each well
was transferred to a white, opaque, 96-well plate, and 50μL
of the reconstituted luciferin detection reagent was added
to initiate a luminescent reaction. After a 20-min stabiliza-
tion period, luminescence was read through a multi-mode
microplate reader (Synergy HT, BioTek Instruments, Inc.;
Winooski, VT, USA). Fold changes of post-treatment lumi-
nescence were calculated by dividing the detected lumines-
cence signals by values reﬂecting cell viability.
2.5. Real-Time Polymerase Chain Reactions (Real-Time PCR).
T h et o t a lR N Ai nc e l lc u l t u r e sw a se x t r a c t e dw i t hR e z o lC & T
RNA extraction reagent (Protech Technologies, Inc., Tai-
wan), and 1μg of total RNA was reverse transcribed using
oligo-dT (Promega) as a primer in 20μL of reverse tran-
scription solution, containing 1μL of reverse transcriptase
(Promega). Real-time PCR was performed using a Corbett
instrument (QIAGEN; Hilden, Germany) and SYBR Green
Master Mix (Protech Technologies, Inc., Taiwan), according
tothemanufacturer’sinstructions.Inallreal-timePCRexpe-
riments, both a nontemplate control (NTC) and a standard
curve were ampliﬁed. The RNA abundance was normalized
to β-actin (a house-keeping gene) RNA in each sample. The
primers and PCR conditions used in this study are shown in
Table 1.
2.6. Western Blotting. Protein expressions of CYP3A4, PXR,
9-cis retinoic acid receptor (RXRα), and HNF4α were mea-
sured by using western blotting. HepG2 cells were seeded at
a density of 2 × 106 cells/10-cm dish, before drug treatment.
Various concentrations of sesamin, alone or in combination
with 20μM rifampin, were added to the HepG2 cell cul-
ture for 48h. Following drug treatment, the medium was
removed, and the cells were rinsed twice with ice-cold PBS.
After adding 200μLo fi c e - c o l dR I P Ab u ﬀer with protease
inhibitors, the cells were scraped from the surface of the
culture dish and allowed to stand on ice for 20min, and
the cell lysates were centrifuged (14,000rpm for 30min at
4◦C).Totalprotein(50μg)fromthesupernatantwasresolved
by using 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto nitrocel-
lulose (NC) paper. These blots were exposed to primary
antibodies against CYP3A4, PXR, RXRα,H N F 4 α,a n dβ-
actin(SantaCruzBiotechnology Inc.,SantaCruz, CA, USA).
The relative density of the immunoreactive bands was quan-
titated using densitometry (ImageQuant LAS 4000, GE
Healthcare, Waukesha, WI, USA) following detection using
an enhanced chemiluminescence detection system (Milli-
pore, Billerica, MA, USA).
2.7. Transfection, CYP3A4 Reporter Assay, and Mammalian
Two-Hybrid Assay. HepG2 and LS174T cells were plated in
96-well plates (Nunc, Rochester, NY, USA), at a density of
1.8 × 104 cells/well, 18h before transfection. Plasmid DNA4 Evidence-Based Complementary and Alternative Medicine
was introduced using PolyJET transfection reagent (Signa-
Gen Laboratories, Rockville, MD), according to the man-
ufacturer’s instructions. For the CYP3A4 reporter assay,
0.15μg of a CYP3A4 reporter construct, 0.02μgo fc o n t r o l
β-galactosidase plasmid, and either 5ng PXR/CAR/rPXR or
0.04μg SRC-1/HNF4α expression plasmid was added per
well. For the mammalian two-hybrid assays, transfection
was carried out by mixing 0.10μg of the pG5luc reporter
gene,0.04μgeachofthepBIND-GAL4andpACT-VP16con-
structs, and 0.02μg of the control β-galactosidase plasmid
per well. After 6 or 7h, the cells were exposed to rifampin,
sesamin, CITCO, PCN, SR12813, paclitaxel, or a similar vol-
ume of DMSO. After a further 20–24h of incubation, the
c e l l sw e r el y s e din situ with 80μLo fc e l lc u l t u r el y s i sr e a g e n t
(Promega). The cleared lysate (30μL) was used for the β-
galactosidase assay. A 50-μL aliquot of each cleared lysate
was used for the reporter assay, following which 80μLo f
luciferase assay reagent (Promega) was added to the lysates.
Luminescent signals were measured using a luminescence
multi-mode microplate reader. Luciferase activities were
normalized to the corresponding β-galactosidase activity.
Datashownaremeansoftriplicateorquadruplicatetransfec-
tions ± standard deviations, as indicated.
2.8. Statistical Analysis. All experiments were repeated at
least thrice independently. Values, expressed as mean ± SD,
were analyzed using one-way ANOVA followed by Tukey’s
test for multiple comparisons. All statistical analyses were
performedusingSPSSforWindows,version17.0(SPSS,Inc.,
Chicago, IL, USA). A P value < 0.05 was considered statis-
tically signiﬁcant.
3. Results
3.1. Cell Viability of HepG2 and LS174T Cells following
Exposure to Sesamin. Since sesamin (Figure 1)h a sb e e n
shown to inhibit proliferation of multiple types of malignant
cells [13–17], a cell viability test was performed to rule out
cytotoxic eﬀects due to sesamin. As shown in Figure 2,
HepG2 (Figure 2(a)) and LS174T (Figure 2(b))c e l l sw e r e
exposed to a range of concentrations of sesamin alone
and in combination with rifampin for 48h, and the cell
viability was assessed using the ACP assay. Rifampin did
not show cytotoxicity toward either cell line. Sesamin
caused mild cytoxicity as compared to DMSO-treated cells.
However, even after exposure to 40μM sesamin (the highest
concentration tested), cell viability remained approximately
80%.
3.2. Sesamin Inhibits Rifampin-Induced CYP3A4 Enzyme
Activity,mRNA,andProteinExpressioninHepG2Cells. Sesa-
min’s ability to inhibit the basal and rifampin-induced
CYP3A4 enzyme activity as well as mRNA and protein exp-
ression was assessed by exposing HepG2 cells to concentra-
tions of sesamin (10–40μM) alone or in combination with
20μM rifampin, for 48h. As shown in Figure 3(a),t r e a t m e n t
with 20μM rifampin increased CYP3A4 activity by 66%,
as compared to the DMSO-treated controls. Treatment of
O
O
O
O
O
O
H
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Figure 1: The chemical structure of sesamin.
HepG2 cells with 10, 20, 30, and 40μMs e s a m i nf o r4 8 h
signiﬁcantly decreased basal CYP3A4 enzyme activity by
15.6%, 23.4%, 37.1%, and 55.8% (P<0.001), respec-
tively, as compared to controls. Coincubation of cells with
20μM rifampin and the above-mentioned concentrations
of sesamin signiﬁcantly attenuated the rifampin-induced
CYP3A4 enzyme activity. The inhibitory eﬀect of sesamin
wasconcentrationdependent,decreasingCYP3A4activityby
21.3%, 25.7%, 41%, and 77.3%, respectively, (P<0.001), as
compared to the rifampin-treated cells (Figure 3(a)).
To determine if decreased CYP3A4 enzyme activity was a
consequence of decreased mRNA expression, real-time PCR
was used to assess CYP3A4 mRNA levels. Sesamin (20, 30,
40μM) was found to signiﬁcantly decrease the basal CYP3A4
mRNAexpressioninHepG2cellsafterincubationfor48hby
9.67% (P<0.05), 28.3% (P<0.001), and 47% (P<0.001),
respectively, as compared to untreated cells (Figure 3(b)).
Conversely, rifampin signiﬁcantly induced CYP3A4 mRNA
expression by 91.3% (P<0.001). However, the rifampin-
induced increase in CYP3A4 mRNA expression was dec-
reased when sesamin (20, 30, and 40μM) was coadminis-
tered [26.1% (P<0.05), 50.1% (P<0.001), and 59.9%
(P<0.001), resp.]. Therefore, sesamin had signiﬁcant eﬀects
onthebasalandinducedlevelsofCYP3A4mRNAexpression
(Figure 3(b)).
To evaluate CYP3A4 protein expression, HepG2 cells
were treated with 20 and 40μM sesamin alone or in com-
bination with 20μM rifampin for 48h. Protein expression
levels were determined using western blotting. We found
that sesamin (20μM) signiﬁcantly decreased the basal level
of CYP3A4 protein expression (48.5%, P<0.05) as com-
pared to the DMSO-treated group (Figures 3(c) and 3(d)).
Rifampin signiﬁcantly enhanced CYP3A4 protein expression
by 55.5% (P<0.05). Coincubation of the cells with 20 and
40μMs e s a m i nw i t h2 0μM rifampin signiﬁcantly decreased
rifampin-inducedCYP3A4proteinexpressionby57.7%(P<
0.05) and 66.5% (P<0.05), respectively, as compared to
rifampin-induced cells. The eﬀects were concentration de-
pendent (Figures 3(c) and 3(e)) and consistent with those
from the mRNA expression assays. Thus, sesamin inhibits
CYP3A4 enzyme levels by reducing expression of both
mRNA and protein.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Cell viability of HepG2 and LS174T cells following exposure to sesamin alone and in combination with rifampin. (a) HepG2 and
(b) LS174T cells were exposed to sesamin (10–40μM), rifampin (20μM), and combinations of rifampin (20μM) and sesamin (10–40μM)
for 48h. Cell viability was monitored by cellular acid phosphatase activity using PNPP as a substrate. Results are presented as mean ± SD
(n = 4).
3.3. Sesamin Inhibits PXR-Mediated CYP3A4 Promoter Activ-
ity in HepG2 and LS174T Cells. PXR is a main ligand-activa-
ted transcription factor of CYP3A4. PXR transactivation re-
porter assays were conducted to assess the inhibitory eﬀectof
sesaminaloneorwithrifampin-inducedPXRtransactivation
activity, on the CYP3A4 promoter. Cells were cotransfected
withaβ-galactosidaseexpressionvector,areportergenecon-
struct containing a responsive element for PXR in the CYP3-
A4promoter,andahumanPXRexpressionplasmidorvector
control. Cells were treated with diﬀerent concentrations of
sesamin, with or without 20μM rifampin. The luciferase
activity was measured after 24h of drug treatment. The
results are shown in Figure 4. In HepG2 cells, sesamin (20,
30, and 40μM) strongly attenuated the transactivation of the
CYP3A4 promoter induced by rifampin in a concentration-
dependent manner when cotransfected with human PXR. As
shown in Figure 4(a), transactivation decreased by 31% (P<
0.05), 40.6% (P<0.01), and 64.8% (P<0.001), respectively,
as compared to the rifampin-induced groups. Similar exper-
iments were also performed using a colon adenocarcinoma
cell line (LS174T) to exclude the possibility of a cell-type-
speciﬁc eﬀect. As shown in Figure 4(b), similar results were
found when these cells were transfected with PXR in the
presence of rifampin and sesamin. Treatment of LS174T cells
with sesamin for 24h signiﬁcantly attenuated PXR-mediated
activation of the CYP3A4 promoter induced by rifampin;
the eﬀect of sesamin was concentration dependent, with
40μM sesamin producing the greatest inhibitory eﬀect [80%
decrease, (P<0.001), as compared to rifampin treatment
alone].
Endogenous PXR and CAR have been identiﬁed in
HepG2 and LS174T cells [51, 52]; thus, rifampin could acti-
vate the CYP3A4 reporter response in cells carrying the con-
trol vector only. As shown in Figures 4(a) and 4(b),e x p o s u r e
of vector-transfected groups to 40μM sesamin signiﬁcantly
decreased rifampin-induced CYP3A4 promoter activity in
HepG2 cells (a decrease of 37%, P<0.01; Figure 4(a))a n d
in LS174T cells (a decrease of 55.7%, P<0.001; Figure 4(b)),
as compared to the rifampin-treated controls. In contrast,
cells without rifampin induction did not show a signiﬁcant
reduction of CYP3A4 reporter activity in the presence of
sesamin. These results suggest a PXR-dependent mechanism
of regulation.
3.4. Inhibition of HumanCAR- andRat PXR-Mediated CYP3-
A4 Induction. CYP3A4 expression is also regulated by CAR
atthesameresponseelementsintheCYP3A4promoter[30].
Similar reporter assays were performed in HepG2 cells to
evaluate the eﬀect of sesamin on human CAR-mediated
CYP3A4 transactivation. Sesamin (20 and 40μM) was found
to markedly attenuate CITCO-induced CYP3A4 promoter
activation through CAR (26.6%, P<0.05, and 56.2%, P<
0.001, as compared to CITCO treatment alone, at 20 and
40μM sesamin, resp.; Figure 5(a)).
CYP3A4 inhibition is predominantly modulated by the
eﬀect of PXR on CYP3A4 expression and partly modulated
by CAR. Previous reports have shown that the diﬀerences in
the ligand-binding domain of human and rat PXR may lead
to ligand-induced species-speciﬁc eﬀects [53]. Therefore,
sesamin inhibition of rat PXR activation was also tested. As
shown in Figure 5(b), when rat PXR-transfected cells were
treated with the rodent-speciﬁc ligand, PCN, CYP3A4 activ-
ity was enhanced by 322%, as compared to DMSO-treated
controls. Sesamin strongly attenuated rat PXR-mediated
CYP3A4 promoter activity with PCN induction by either
20μM sesamin (decreased by 28.9%, P<0.05) or 40μM
sesamin (decreased by 54.3%, P<0.001), as compared to the
PCN-treated cells. The results indicate that sesamin activity
is not highly species speciﬁc.
3.5. Eﬀects of Sesamin on PXR, RXRα,a n dH N F 4 α Protein
Expression. Based on the ﬁnding that sesamin reduces PXR
activity in cell-based assays, in vitro, the impact of sesamin
on PXR protein expression was investigated. PXR binds to
DNA as a heterodimer with RXRα. The heterodimer can
bind to and induce transcription from response elements
located in the CYP450 genes [29–33]. In addition, rifampin-
inducedCYP3A4requiresPXRcross-talkwithHNF4αonthe
CYP3A4promotertranscriptioncomplex[54].Westernblots
wereperformedtoevaluatethePXR,RXRα,andHNF4αpro-
tein levels in sesamin-treated cells. HepG2 cells were treated6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of sesamin (SSM), alone or sesamin in combination with rifampin, on CYP3A4 enzyme activity, mRNA expression, and
proteinexpression.(a)Variousconcentrationsofsesamin,aloneorincombinationwith20μMrifampin,wereaddedtoculturedHepG2cells
for 48h. CYP3A4 enzyme activities were measured by using P450-Glo assays with 50μM luciferin-PFBE as a substrate. Values are presented
as mean ± SD (n = 3); ###P<0.001 and ∗∗∗P<0.001 as compared to DMSO-treated or 20-μM rifampin-treated cells, as appropriate.
(b) HepG2 cells were treated with sesamin and rifampin, individually or in combination, for 48h, mRNA was collected, and the expression
of CYP3A4 and an internal control, β-actin, were analyzed using RT-PCR. Values were normalized relative to the expression of β-actin, with
the CYP3A4 expression of DMSO-treated cells set at 100%. The results are as expressed as mean ± SD (n = 3) of the relative expression of
CYP3A4; ∗P<0.05 and ∗∗∗P<0.001 as compared to DMSO-treated or 20-μM rifampin-treated cells, as indicated in the ﬁgure. (c) HepG2
cells were treated with sesamin and rifampin, individually or in combination, for 48h. Whole cell extracts were harvested, and the expression
of CYP3A4 and the internal control β-actin were analyzed using western blotting. (d) Quantitation of band intensity of the CYP3A4 protein
was normalized to β-actin expression. The basal expression of the CYP3A4 protein was set at 100%. The values are presented as mean ±
SD (n = 3); ∗P<0.05 as compared to DMSO-treated cells. (e) Quantitation of band intensity of CYP3A4 protein was normalized to the
β-actin expression. The rifampin-induced CYP3A4 protein expression was set at 100%, and the values are presented as mean ± SD (n = 3);
∗P<0.05 as compared to rifampin-treated cells.Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Transient transcription assays of CYP3A4 reporter activity in HepG2 and LS174T cells to determine the eﬀects of sesamin- or
rifampin-mediated activation. (a) HepG2 and (b) LS174T cells were cotransfected with a vector control (pcDNA3) or PXR expression
plasmid (pcDNA3-PXR), a CYP3A4 luciferase reporter plasmid, and a pRC-CMV-β-galactosidase vector. Subsequently, the transfected cells
were exposed to sesamin and/or rifampin for 24h. The results are expressed as mean ± SD (n = 4); ∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001, as
compared to rifampin-treated cells.
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Figure 5: Transactivation of the CYP3A4 promoter by human CAR and rat PXR in the presence of sesamin and/or rifampin. HepG2 cells
were cotransfected with a vector control (pcDNA3) and (a) human CAR expression plasmids (pcDNA3-CAR) or (b) rat PXR expression
plasmids(pcDNA3-rPXR),aCYP3A4luciferasereporterplasmid,andpRC-CMV-β-galactosidasevectors.Subsequently,thetransfectedcells
wereexposedtosesaminand/orrifampinfor24h.Theresultsareexpressedasmean ±SD(n = 4); ∗P<0.05and ∗∗∗P<0.001,ascompared
to rifampin-treated cells.
with 20 and 40μM sesamin alone or in combination with
20μM rifampin and lysed after 48h of exposure. As shown
in Figure 6, none of the treatment conditions resulted in an
alteration of protein expression of PXR (Figure 6(a)), RXRα
(Figure 6(b)), or HNF4α (Figure 6(c)). The results indi-
cated that the reduction of CYP3A4 activity was not due to
decreased expression of the upper control elements.
3.6. Inhibition of Coregulation of Human SRC-1 and HNF4α
with PXR by Sesamin. Earlier studies showed that cotrans-
fectionofSR C-1andHNF4αintocellsproducedasynergistic
increase in CYP3A4 promoter activity [49, 54, 55]. This part
of the study sought to determine whether the eﬀects of
these two CYP3A4 promoter coregulators were altered by the
presence of sesamin. Full-length human SRC-1 or HNF4α
expression plasmids were cotransfected with full-length
human PXR/vector control and CYP3A4 reporter constructs
into HepG2 cells. The cells were then exposed to sesamin,
alone or in combination with rifampin, followed by mea-
surement of luciferase activity after 24h of incubation. Since
HepG2 cells contain endogenous PXR, cells transfected with
the vector control and SRC-1 demonstrated a 98% increase
in CYP3A4 promoter activity in the presence of rifampin
(Figure 7(a)). Sesamin (40μM) decreased the promoter acti-
vity to 24.9% (P<0.001) of the level observed in rifampin-
treated cells. Transfection with PXR and SRC-1 expression
plasmids resulted in a CYP3A4 promoter activity enhance-
ment of 243.6 folds, in the presence of rifampin. Again, sesa-
min (20 and 40μM) strongly disrupted the enhancement of
the promoter activity; activity was decreased to 64.2% (P<
0.001) or 18.5% (P<0.001), respectively, of the level obser-
ved in rifampin-treated cells.8 Evidence-Based Complementary and Alternative Medicine
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Figure 6:EﬀectofsesaminonbasalandinducedPXR,RXRα,andHNF4αproteinexpression.HepG2cellswereseededintissue-culturewells
prior to being exposed to various concentrations of sesamin alone or in combination with 20μM rifampin for 48h. Whole cell lysates were
collected, and protein expression of (a) PXR, (b) RXRα, and (c) HNF4α were detected using western blotting.
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Figure 7: Coregulation of SRC-1 and HNF4α with PXR was disrupted by sesamin. HepG2 cells were cotransfected with (a) a vector control
(pcDNA3)orPXRexpressionplasmid(pcDNA3-PXR)andSRC-1expressionplasmid(pCR3.1-SRC-1),or(b)avectorcontrol(pcDNA3)or
PXR expression plasmid (pcDNA3-PXR) and HNF4α expression plasmid (pcDNA3-HNF4α), in combination with the CYP3A4 luciferase
reporter plasmid and the pRC-CMV-β-galactosidase vector. Subsequently, the transfected cells were exposed to sesamin and/or rifampin for
24h. Luciferase activity was measured and normalized to the corresponding β-galactosidase activity. The results are expressed as mean ± SD
(n = 4); ∗∗∗P<0.001, as compared to rifampin-treated cells.
The coregulation of HNF4α and PXR was also evaluated.
When cells were cotransfected with the vector control and
full-length HNF4α prior to rifampin exposure, CYP3A4
activity was enhanced 23.2 folds. This eﬀect was disrupted by
sesamin, with the greatest inhibition at a sesamin concentra-
tion of 40μM (decreased by 89.3%, P<0.001, as compared
to rifampin-treated groups). The coregulation strength was
not as great as that observed in the SRC-1/PXR cells; the
presence of HNF4α and PXR enhanced CYP3A4 promoter
activity by 53.6 folds. As Figure 7(b) shows, 20 and 40μM
sesamin signiﬁcantly reduced CYP3A4 promoter activity in
these cells when exposed to rifampin (decreases of 44.8%,
P<0.01, and 88.3%, P<0.001, resp., as compared to
rifampin-treated groups). These results indicated that sesa-
min disrupts the coregulation eﬀects of SRC-1/PXR and
HNF4α/PXR on CYP3A4 promoter activity.
3.7. Sesamin Disrupts the Interaction of SRC-1/PXR and
HNF4α/PXR in LS174T Cells. Ketoconazole has previously
been shown to inhibit the expression of CYP3A4 by disrup-
ting the interaction of SRC-1 and PXR as well as that of
HNF4α and PXR [50]. To determine whether sesamin could
inhibit SRC-1/PXR or HNF4α/PXR interaction, a GAL4/
VP16 mammalian two-hybrid reporter system was used. The
RID of SRC-1 and the full-length PXR gene were fused withEvidence-Based Complementary and Alternative Medicine 9
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Figure 8: Disruption of protein-protein interactions between PXR and SRC-1/HNF4α in the presence of sesamin in a mammalian two-
hybrid assay. Mammalian two-hybrid studies were conducted in LS174T cells to elucidate the eﬀects of sesamin on the interactions between
(a) SRC-1 receptor-interacting domain (RID) (pBIND-SRC-1); (b) full-length HNF4α (pACT-HNF4α), and the full-length clone of PXR
(pACT-PXR and pBIND-PXR, resp.). The schematic diagram of the plasmids used is illustrated at the left top of each ﬁgure. The cells were
harvested in equal aliquots at 24h to determine luciferase activity. All transfections were normalized for transfection eﬃciency by β-
galactosidase activity. The results are expressed as mean ± SD (n = 4); ∗P<0.05; ∗∗P<0.01; and ∗∗∗P<0.001, as compared to
DMSO-treated or 20μM rifampin-treated cells, as indicated.
the GAL4 DNA-binding domain to become pBIND-SRC-1
and pBIND-PXR, respectively. Similarly, the full-length PXR
and HNF4α were fused with the VP-16 vector to become
pACT-PXR and pACT-HNF4α,r e s p e c t i v e l y .
As shown in Figure 8(a), in the absence of rifampin, 20
and 40μM sesamin decreased the interaction between PXR
and SRC-1 by 27% and 49.1% (P<0.05 and P<0.001),
as compared to control groups in LS174T cells. In contrast,
rifampin strongly promoted the speciﬁc interaction between
PXR and SRC-1 by 8.1 folds; sesamin attenuated the inter-
action between PXR and SRC-1 concentration-dependent
manner, with a 25.8% (P<0.05) and 67.9% (P<0.001)
inhibition at 20 and 40μM sesamin, respectively.
The interaction between HNF4α and PXR was also dis-
rupted by sesamin. As shown in Figure 8(b), the interaction
of cells transfected with pBIND-PXR and pACT-HNF4α,
without rifampin induction, decreased by 45.2% (P<0.001)
compared to DMSO-treated cells. Rifampin enhanced the
protein-protein interaction of PXR and HNF4α by 2.2 folds.
As expected, sesamin disrupted this interaction in a concen-
tration-dependent manner. A decrease of 31.3% was seen in
cells exposed to 20μMs e s a m i n( P<0.01), and a decrease
of 57.6% was seen in cells exposed to 40μMs e s a m i n( P<
0.001), as compared to rifampin-treated groups which were
not exposed to sesamin. These data suggest that sesamin
inhibits SRC-1/PXR and HNF4α/PXR interactions, thus
transactivation in the regulation of CYP3A4 gene expression
occurs through the transcriptional control.
3.8. CYP3A4 Promoter Activity in the Presence of Sesamin and
Paclitaxel or SR12813. Because many antineoplastic drugs
have a narrow therapeutic index, the ability of drugs (e.g.,
paclitaxel) to activate PXR may be limited because of
autoinduced metabolism [56]. This implies that sesamin
antagonism of PXR activity might improve the pharmacoki-
netic properties of these drugs. As shown in Figure 9(a),
2.5μM paclitaxel enhanced CYP3A4 promoter activity in
LS174T cells up to 3 folds as compared to the controls. When
the cells were cotreated with paclitaxel and 20 or 40μM
sesamin, CYP3A4 promoter activity reduced by 39.1% (P<
0.05) and 60.5% (P<0.001), respectively, when compared
with paclitaxel-induced controls. These results indicated that
sesamin may rescue PXR agonists from autoinduced meta-
bolism.
SR12813, the most eﬃcient PXR agonist discovered to
date [57], was used in some evaluations to exclude the pos-
sibility of rifampin-speciﬁc eﬀects. In the presence of 10μM
SR12813, CYP3A4 promoter activity in LS174T cells was en-
hanced by 46.1 folds, as compared to DMSO-treated cells
(Figure 9(b)). The presence of sesamin (20 or 40μM) re-
sulted in 62.8% (P<0.001) or 78.4% (P<0.001) inhibition,
respectively, of transcriptional activity induced by SR12813.
The results showed that inhibition of CYP3A4 by sesamin
was not a rifampin-speciﬁc eﬀect.
3.9. Sesamin Increases Gene Expression of Enzymes Involved
in Phase II Metabolism. The discovery that sesamin inhibits
CYP3A4 expression led to an investigation of sesamin’s eﬀect
on the expression of UGT1A1 mRNA in HepG2 cells by RT-
PCR. UGT1A1 is an enzyme involved in hepatic phase II
metabolism that is also regulated by PXR [58]. As shown
in Figure 10(a),s e s a m i n( 2 0t o4 0μM) increased UGT1A1
mRNA expression in HepG2 cells in a concentration-depen-
dent manner, resulting in a 3.1-fold (P<0.01) or 4-fold
(P<0.001) increase at sesamin concentrations of 30 and
40μM, respectively. The expression of UGT1A1 mRNA also10 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Downregulation of CYP3A4 reporter activity on PXR agonist, paclitaxel- and SR12813-mediated induction by sesamin. LS174T
cells were cotransfected with a vector control (pcDNA3) or PXR expression plasmid (pcDNA3-PXR), a CYP3A4 luciferase reporter plasmid,
andapRC-CMV-β-galactosidasevector.Subsequently,thetransfectedcellswereexposedtosesaminand/or(a)2.5μMpaclitax elor(b)10μM
SR12813 for 24h. Luciferase activity was measured and normalized to the corresponding β-galactosidase activity. The results are expressed
as mean ± SD (n = 4); ∗P<0.05 and ∗∗∗P<0.001, as compared to rifampin-treated cells, as indicated.
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Figure 10: Sesamin-related changes in gene expression of the phase II enzyme gene (UGT1A1)a n dt h eN r f 2t a r g e tg e n e( NQO1). HepG2
cells were treated with sesamin and rifampin, independently or in combination for 48h; mRNA was collected, and the expression of (a)
UGT1A1 and (b) NQO1 were analyzed by RT-PCR and normalized to the corresponding β-actin expression. The expression in DMSO-
treated controls was set at 1. The results are expressed as mean ± SD (n = 3). ∗P<0.05; ∗∗P<0.01; and ∗∗∗P<0.001, as compared to
DMSO-treated or 20-μM rifampin-treated cells, as indicated in the ﬁgure.
increased 11.7 folds in the presence of 20μM rifampin,
consistent with the results of previous studies [59]. With the
addition of 20 to 40μM sesamin, in combination with 20μM
rifampin, expression of UGT1A1 mRNA increased with in-
creasing concentrations of sesamin. This increase was par-
ticularly notable at sesamin concentrations of 30μM, where
mRNA levels increased by 65.6% (P<0.05), and 40μM,
where mRNA levels increased by 98% (P<0.01). Presu-
mably, sesamin induced UGT1A1 gene expression through
a PXR-independent pathway and may be a nuclear factor
E2-related factor 2- (Nrf2-) dependent pathway [60]. Sesa-
min induced the expression of another Nrf2 target gene,
NAD(P)H quinone oxidoreductase 1 (NQO1), in HepG2
cells (Figure 10(b)). In this case, mRNA expression was in-
creased by 1.4 folds (P<0.05) in the presence of 20μM
sesamin, and 2-fold (P<0.001) at a 30μM sesamin concen-
tration. The net inductive eﬀect of sesamin on UGT1A1 gene
expression is interesting because UGT1A1 is also regulated,
in part, by PXR.
4. Discussion
In this study, sesamin was demonstrated to antagonize the
induction of CYP3A4 in HepG2 and LS174T cells. It was
also determined to be an inhibitor of rat and human PXR in
nuclearreceptortransactivationassays.Additionally,sesamin
was demonstrated to suppress human CAR activation. Fur-
thermore, the underlying mechanisms of human PXR inhi-
bition were explored. Sesamin was found to inhibit coreg-
ulation between SRC-1 and HNF4α by disrupting their
recruitment and interaction with PXR. These changes were
not due to reduced protein levels of those nuclear receptors
or coregulators. The inductive eﬀects of SR12813 andEvidence-Based Complementary and Alternative Medicine 11
paclitaxelcouldbeattenuatedbycoadministrationwithsesa-
min. These results suggest a potential mechanism for pre-
venting inducer-drug interactions between PXR ligands and
minimizingthepotentialforP450inducer-druginteractions.
Although numerous human PXR activators have been iden-
tiﬁed, to date there are few reports of potent inhibitors of
PXR.SesaminisanovelfunctionalinhibitorofPXRandmay
be a useful chemical tool for modulating PXR-regulated gene
expression in vitro or in vivo.
InappropriatePXRactivationleadstoimportantandun-
desirable pathophysiologic consequences [56]. One of PXR’s
main target genes is CYP3A4, a cytochrome that is variably
expressed in the liver and small intestine cells [19]. Drug-
inducedactivationofCYP3A4mayaﬀectthesafetyandeﬀec-
tive dosing of narrow therapeutic index chemotherapeu-
tic agents, if they are CYP3A4 substrates. The genetics of
CYP3A4 have not explained the variable expression of this
cytochrome. This has raised the possibility that individual
diﬀerences in exposure to dietary or endogenous agents may
modulate CYP3A4 transcription, contributing to functional
CYP3A4 variability [33]. In this study, sesamin was found
to decrease constitutive CYP3A4 activity, as well as mRNA
and protein expression. Moreover, it attenuated rifampin-,
paclitaxel-,andSR12813-mediatedCYP3A4inductioninhu-
man hepatoma and colon adenocarcinoma cells. These re-
sults suggest that dietary exposure to sesamin could poten-
tially contribute to the large variability in basal CYP3A4
expression between individuals.
Extensive cross-talk occurs between members of the nuc-
lear receptor superfamily. Both PXR and CAR are closely re-
latednuclearreceptorsbelongingtothenuclearreceptorsub-
family(NR1)thatareinvolved inCYP3A4regulationandare
endogenously expressed in HepG2 cells [55]. Their ligand-
binding domains (LBDs),whichshare40%aminoacidsequ-
ence similarity, bind overlapping areas of the CYP3A4 pro-
m o t e r ,b u tw i t hd i ﬀerential preference [34]. Results from
cell-based nuclear receptor transactivation assays indicated
that sesamin not only strongly antagonizes PXR but also
greatly attenuates CAR-mediated CYP3A4 promoter activity
induced by CITCO. Moreover, previous reports have shown
that PXR and CAR exhibit promiscuous, low-aﬃnity ligand
binding characteristics [53]. Hence, PXR and CAR appear to
share similar mechanisms of CYP3A4 regulation.
The full activity of NRs depends on a large number of
cellular factors that called coactivator, that do not bind DNA
directly, but are selectively recruited to the promoter by the
NRs through protein-protein interactions [61]. This suggests
the potential activation of NR-regulated genes at the tran-
scriptional levels. A probable mechanism by which sesamin
attenuates rifampin-induced CYP3A4 expression is through
inhibition of the interaction between PXR and SRC-1. In the
present study, sesamin was found to signiﬁcantly attenuate
rifampin-induced interactions between PXR and SRC-1 in
a concentration-dependent manner. This suggests that sesa-
min may inhibit PXR coactivator recruitment, thereby pot-
entially preventing ligand-mediated PXR transcriptional
activation of target genes.
HNF4α also plays an essential role in the PXR-dependent
induction of human CYP3A4 [55, 62]. Thus, an HNF4α
element adjacent to the PXR- and CAR-binding sites in the
human CYP3A4 promoter is an obligatory component of a
xenobiotic-responsive distal enhancer [55]. Previous studies
revealed that ketoconazole inhibition of CYP3A4 expression
not only involves the recruitment of SRC-1, but also HNF4α
[50, 63]. Analysis of the molecular mechanism of gene trans-
cription inhibition demonstrated that sesamin speciﬁcally
disrupts the interaction of PXR with HNF4α and the coac-
tivator, SRC-1.
Diﬀerential activation of PXR orthologs between species
has been well reported [64]. Moreover, PXR and CYP3A
display cell-type and species-speciﬁc diﬀerences. Due to the
structural diﬀerences in its ligand-binding pockets, ligand-
mediated activation of PXR can occur through a wide variety
of compounds in a species-dependent manner [64]. Sesamin
was tested in transient transfection assays using rat PXR and
was found to strongly attenuate rat PXR-mediated CYP3A4
promoter activity induced by PCN. The results indicate that
sesamin does not have a species-speciﬁc eﬀect on human
and rat PXR. The inductive eﬀects of paclitaxel and SR12813
on CYP3A4 were also attenuated by coadministration with
sesamin, indicating it was not a rifampin-speciﬁc eﬀect. The
protein expression of PXR and the coregulators RXRα and
HNF4α were not aﬀected by sesamin.
LiteraturereportsindicatethatUGT1A1istranscription-
allyregulatedbybothPXRandCARthroughDR-3andNR-1
elementsinthe5 -promoterregion[58,65].Resultsfromthe
present study indicated that although sesamin antagonized
PXR activity, its induction of UGT1A1 expression appeared
to be through a PXR-independent pathway. The expression
of UGT1A1 enzymes is regulated by Nrf2, which binds to
AREs present within the promoter [66]. The result of this
binding is an upregulation of the transcription of those
genes. We examined the expression of another Nrf2 target
g e n e ,N Q O 1 ,a sw e l l[ 66]. Sesamin also signiﬁcantly induced
the mRNA expression of this gene, adding further evidence
that sesamin induced UGT1A1 expression primarily through
an Nrf2-dependent pathway.
Aside from its important role in xenobiotic defense, evi-
dence suggests that during carcinogenesis, PXR promotes
t u m o rc e l lg r o w t h[ 67]. Cancer chemotherapy normally in-
volves the coadministrated of multiple drugs, and these may
have somewhat unpredictable therapeutic outcomes as a
result of individual diﬀerences in PXR-mediated trans-
criptional eﬀects. Therefore, a PXR inhibitor can be used
to develop a unique method for controlling drug-induced
metabolism during chemotherapy, especially if the inhibitor
is comparatively nontoxic. Studies have shown that the
antineoplastic agent trabectedin ET-743 [45], the antifungal
agent ketoconazole(s) [50, 63], the dietary isothiocyanate
sulforaphane (SFN) [44], the human HIV protease inhibitor,
A-792611 [68], the phytoestrogen coumestrol [46], a topoi-
somerase I inhibitors camptothecin (CPT) [47], and met-
formin [69] are all functional inhibitors of PXR.
A genotoxicity report from Hori et al. [70] included ana-
lysis of the plasma levels of sesamin in Crlj:CD1 (ICR) mice
3hafterthesecondof2doses,administeredorally24hapart,
of sesamin at 0.5, 1.0, and 2.0g/kg of body weight. The
plasma levels of sesamin were 2.11, 8.18, and 8.00μg/mL,12 Evidence-Based Complementary and Alternative Medicine
or approximately 6, 23.1, and 22.6μM, respectively. Our
results indicate that 20μM sesamin is suﬃcient to decrease
CYP3A4 activity and mRNA and protein expression levels
signiﬁcantly. Therefore, a plasma concentration of 20μM
sesamin, which is suﬃcient to modulate CYP3A4 according
to our in vitro data, may well be achievable by oral ingestion,
at least in animal studies. Diﬀerences in genetics, geogra-
phical origin, growing conditions, seed size, and capsule
position may contribute to the variable amounts of sesamin
in seeds. Rangkadilok et al. [71] showed ranges of sesamin
content of 0.05–4.71mg/g of seed in the landrace black seed
lines and 0.74–7.23mg/g of seed in white sesame seeds. The
sesamin content of Taiwanese sesame oil is 9.47 ± 2.28mg/g
of oil [72]. Here, we describe a novel, eﬀective PXR inhibitor
from a naturally occurring substance, sesamin, and we
believe that another PXR inhibitor with higher eﬃciency but
lower toxicity can be found on the same lines.
HepaRG cells, which were derived from a female hepato-
carcinoma patient, are capable of diﬀerentiating into biliary
epithelialcellsandhepatocytes[73].TheyretainmanyDMEs
activities and upregulate mRNA expression of such enzymes
in the presence of xenobiotics. This ability is in stark contrast
to that of the frequently used HepG2 cells, and HepaRG cells
have, therefore, been touted as better surrogates for primary
human hepatocytes for drug metabolism and disposition
studies. In this study, we continued to use HepG2 cells as
a simple model system that avoids the interindividual and
interspecies variations and subsequent interpretation diﬃ-
culties that complicate in vivo approaches. Moreover, these
cells are known to constitutively express CYP1A1/2, 2A6,
2B6, 2C9/19, 2D6, 2E1, and 3A4/5 [74]. Researchers using
a cell-based PXR reporter assay to measure possible CYP3A4
induction/inhibition in HepG2 cells showed CYP3A4 mRNA
expression and enzymatic activity levels similar to those in
cultured primary human hepatocytes [74]. Therefore, this
cell line remains an excellent surrogate for primary human
hepatocytes for studying induction of CYP450s. Our results
demonstratethatPXRinducersstillsigniﬁcantlyenhancethe
activity and mRNA and protein expression levels of CYP3A4
in HepG2 cells, implying that, for several compounds, the
CYP activities in HepG2 cells are high enough to activate
xenobiotic receptors and thereby induce further CYP expres-
sion.
In conclusion, we have identiﬁed a naturally occurring
lignan, sesamin, that is a potent inhibitor of human and rat
PXR. The study provides evidence that sesamin attenuates
the induction of CYP3A4 by inhibiting agonist-activated
PXR and CAR. Sesamin disrupts the interaction of PXR with
SRC-1 and HNF4α without aﬀecting expression of NR-re-
lated modulators. These ﬁndings suggest a complementary
mechanism by which ingestion of this naturally occurring
phytochemical may reduce the frequency of adverse drug
reactions secondary to PXR-mediated induction of drug
clearance via CYP3A4. This may improve the therapeutic
eﬃcacy of certain drugs and may also play a role in reduc-
ing the formation of CYP3A4-mediated reactive metabo-
lites.
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